A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women.
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs VG 101 (Primary)
- Indications Genitourinary atrophy
- Focus Therapeutic Use
- 07 Jun 2011 Planned end date changed from 1 Aug 2011 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 01 Sep 2009 Planned end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 14 Apr 2008 The trial is expected to commence later in 2008, according to a Bionovo media release.